Skip to content

Erasca, Inc. ERAS Interest coverage

Interest coverage at other companies

Amgen logo
AmgenAMGN
3.9×+1.5×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-38.1×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-84.7×
Summit Therapeutics logo
Summit TherapeuticsSMMT
-26×
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
582×
Arrowhead Research logo
Arrowhead ResearchARWR
-2.4×+0.9×

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s interest coverage?
Erasca, Inc. (ERAS) reported interest coverage of -18× in Q1 2026.
How has Erasca, Inc.'s interest coverage changed year-over-year?
Erasca, Inc.'s interest coverage decreased by 113.3% year-over-year, from -8.4× to -18×.
What is the long-term trend for Erasca, Inc.'s interest coverage?
Over 5 years (2020 to 2025), Erasca, Inc.'s interest coverage has grown at a -51.8% compound annual growth rate (CAGR), from -325.2× to -8.5×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.